NovoCure Ltd NVCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVCR is a good fit for your portfolio.
News
-
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
-
Novocure to Report First Quarter 2024 Financial Results
-
Novocure's stock surges after positive results in brain-cancer trial
-
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
-
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
-
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
-
Novocure Shares Rise 17% After FDA Accepts Pre-Market Application
-
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Trading Information
- Previous Close Price
- $12.46
- Day Range
- $12.04–12.45
- 52-Week Range
- $10.87–83.60
- Bid/Ask
- $12.07 / $12.16
- Market Cap
- $1.29 Bil
- Volume/Avg
- 1.4 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.60
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,453
- Website
- https://www.novocure.com
Comparables
Valuation
|
Metric
|
NVCR
|
NYKD
|
FUSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.68 | 2.60 | 7.62 |
Price/Sales | 2.60 | 27.66 | 674.51 |
Price/Cash Flow | — | — | — |
Price/Earnings
NVCR
NYKD
FUSN
Financial Strength
|
Metric
|
NVCR
|
NYKD
|
FUSN
|
|---|---|---|---|
Quick Ratio | 5.51 | 6.95 | 14.66 |
Current Ratio | 5.78 | 6.95 | 15.01 |
Interest Coverage | −62.69 | — | −19.06 |
Quick Ratio
NVCR
NYKD
FUSN
Profitability
|
Metric
|
NVCR
|
NYKD
|
FUSN
|
|---|---|---|---|
Return on Assets (Normalized) | −7.80% | −19.18% | −33.14% |
Return on Equity (Normalized) | −22.19% | −26.31% | −43.87% |
Return on Invested Capital (Normalized) | −10.73% | −30.96% | −36.42% |
Return on Assets
NVCR
NYKD
FUSN
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Wyqpdbsh | Fsvrkc | $183.8 Bil | |
SYK
| Stryker Corp | Knktdpzwp | Vnmzm | $127.8 Bil | |
MDT
| Medtronic PLC | Hjvzstq | Yzcxsfz | $105.0 Bil | |
BSX
| Boston Scientific Corp | Mfpmhskhg | Drdtp | $99.9 Bil | |
EW
| Edwards Lifesciences Corp | Xnhbsncfh | Lslqzg | $52.5 Bil | |
DXCM
| DexCom Inc | Btrwrvydt | Ymn | $51.9 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Qqxmpnbk | Bwzwf | $24.9 Bil | |
ALGN
| Align Technology Inc | Thcnhxtn | Tclnzm | $22.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Yvkjcgqd | Ljqwtjr | $18.2 Bil | |
PODD
| Insulet Corp | Qfhndhggjp | Xdpjpzg | $11.6 Bil |